WEBULL
WebtradeDownload

Is Veeva Systems (VEEV) Undervalued As Its Share Price Tests Fresh Highs?

Simply Wall St · 2d ago

Veeva Systems (VEEV) continues to draw attention after recent share performance, with the stock last closing at US$317.82. Recent trading moves now sit against a multi-year backdrop of double digit annual revenue and net income growth.

Over the past few months, Veeva Systems has shifted from a softer patch to stronger momentum, with a 30 day share price return of 13.52% feeding into a 44.80% year to date gain and a 57.68% 90 day climb. At the same time, the 1 year total shareholder return of 10.87% and 3 year total shareholder return of 69.91% indicate that recent strength comes after a much more modest longer term experience for investors.

Scan how Veeva Systems compares with other fast moving software plays by checking our curated list of 38 profitable AI stocks that aren't just burning cash.

After a 90 day surge and fresh multi year highs, the real fork in the road is whether to accept Veeva Systems at this price or wait for a cleaner entry. The valuation does some of that work for you.

Most Popular Narrative: 17% Undervalued

Veeva Systems is trading close to an internal fair value estimate of $383.14, which implies a discount relative to the last close at $317.82 and frames the current rally through valuation discipline rather than just recent price action.

"Back in June, my case for Veeva Systems (VEEV) was not really about software. It was about the cost of being wrong. Pharmaceutical companies do not casually rip systems out of their clinical trials, regulatory submissions, and safety workflows; doing that is less like switching email providers and more like swapping an engine part mid-flight."

See why 52 investors see Veeva Systems as 17% undervalued.

Result: Fair Value of $383.14 (UNDERVALUED)

Still, the Veeva Systems narrative could be knocked off course if pharmaceutical consolidation slows software decisions or if Falcon adoption falls short of investor expectations.

Find out about the key risks to this Veeva Systems narrative.

Another View: What Veeva Systems’ P/E Is Telling You

Look past the fair value models and a different picture of Veeva Systems emerges. The shares trade on a P/E of 50.7x, which is far richer than both the global Healthcare Services group at 26.4x and the estimated fair ratio of 32.4x. That gap points to a rich entry point and raises the question of how much good news is already in the price.

For readers who rely more on earnings multiples than cash flow models, this kind of premium can be useful as a reality check, because it suggests less room for disappointment if sentiment cools or growth expectations ease, even if long term quality remains intact. See what the numbers say about this price — find out in our valuation breakdown.

NYSE:VEEV P/E Ratio as at Oct 2026
NYSE:VEEV P/E Ratio as at Oct 2026

Next Steps

Mixed signals on Veeva Systems so far. If you want to move quickly but think independently, start by weighing both sides of the story with 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Veeva Systems?

If Veeva Systems has sharpened your focus on quality, do not stop here. Broaden your watchlist with a few targeted themes that can surface fresh opportunities before others spot them.